AbbVie Inc. (ABBV) announced Wednesday that Health Canada approved Qulipta, also known as atogepant, for preventing migraines in adults with at least four migraine days per month.
The approval was based on a Phase 3 PROGRESS trial that showed a significant reduction in monthly migraine days with Qulipta 60 mg once daily for adult patients with chronic migraine.
The company stated that Qulipta is the first oral, small-molecule CGRP receptor antagonist approved for both episodic and chronic migraine prevention and is available in three strengths - 10 mg, 30 mg, and 60 mg.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.